Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
Information source: St. Jude Children's Research Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anemia, Sickle Cell
Intervention: Magnesium Pidolate, Hydroxyurea (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: St. Jude Children's Research Hospital Official(s) and/or principal investigator(s): Winfred Wang, MD, Principal Investigator, Affiliation: St. Jude Children's Research Hospital
Summary
The purpose of this study is to estimate the MTD of Mg pidolate in combination with HU in
patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of
HU for at least 6 months.
Clinical Details
Official title: Phase I Study of Combination Treatment With Hydroxyurea and Magnesium Pidolate in Patients With Sickle Cell Disease
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To estimate the maximum tolerated dose of magnesium pidolate in combination with hydroxyurea in patients with sickle cell disease who have been on a therapeutic dose of hydroxyurea for at least six months.
Secondary outcome: To document the toxicity of the combination of hydroxyurea and magnesium pidolate.To investigate the effect of the combination of hydroxyurea and magnesium on hematological parameters and red cell metabolism.
Detailed description:
This is a Phase I clinical trial evaluating the combination of hydroxyurea and magnesium
pidolate for patients with sickle cell disease with either hemoglobin SS disease or
hemoglobin S beta thalassemia. Hydroxyurea and magnesium pidolate will be tested in
pediatric and adolescent patients with sickle cell disease who already have been treated
with hydroxyurea for a minimum of six months. Magnesium pidolate will be given in
combination with hydroxyurea for six months. In successive small groups of patients, the
dose of magnesium will be increased in order to eventually determine the maximum tolerated
dose (MTD) and dose limiting toxicity (DLT) for magnesium when given in combination with
hydroxyurea. The maximum tolerated dose is the highest drug dose that can be given safely to
participants. The dose limiting toxicity is determined when drug side effects prevent an
increase in dose.
Eligibility
Minimum age: 3 Years.
Maximum age: 15 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Age > 3 years and < 15 years at the time of study enrollment
2. Diagnosis of Hb SS or Hb S beta thalassemia
3. Hydroxyurea treatment for at least 6 months prior to study entry at dose of 15 - 30
mg/kg/day
4. Compliance with taking HU treatment of at least 70 % for 6 months prior to study
entry
Exclusion Criteria:
1. Red blood cell transfusion within the last 3 months resulting in a level of Hb A of
10% or more
2. Pregnancy or unwillingness to use effective birth control in sexually active
subjects (females who state that they are sexually active)
3. Renal dysfunction defined by a serum creatinine greater than 1. 5 times the upper
limit of normal for age
4. Liver dysfunction defined by an ALT greater than twice the upper limit of normal for
age
5. Concomitant usage of an "antisickling" agent other than hydroxyurea
6. Current use of Mg containing drugs
7. Iron deficiency, defined by serum ferritin ≤ 10 ng/ml
8. Concomitant chronic illness other than sickle cell anemia
Locations and Contacts
St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States
Additional Information
St. Jude Children's Research Hospital
Starting date: November 2004
Last updated: February 23, 2010
|